Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
casdatifan + tivozanib
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Casdatifan plus tivozanib is an investigational combination therapy being developed for the treatment of advanced clear cell renal cell carcinoma (ccRCC). The combination consists of casdatifan (AB521), an oral small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α) developed by Arcus Biosciences, and tivozanib (Fotivda), an oral small-molecule vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) owned by AVEO Oncology (an LG Chem company). The combination is being evaluated in a randomized cohort of the Phase 1 ARC-20 platform study in patients with advanced ccRCC who have previously progressed on HIF-2α-inhibitor therapy. Arcus Biosciences also plans to initiate a registrational trial of the combination in the late-line setting.
- Other names
- AB521 + AV-951AB521 + FotivdaAB521 + tivozanibAV-951 + AB521AV-951 + casdatifancasdatifan + AV-951casdatifan + FotivdaFotivda + AB521Fotivda + casdatifantivozanib + AB521tivozanib + casdatifan
02
Targets
EPHB2 (Ephrin type-B receptor 2)EPAS1 (Hypoxia-inducible factor 2-alpha)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on casdatifan + tivozanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on casdatifan + tivozanib.